

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX, INC.
Petitioner,

v.

UCB BIOPHARMA SPRL
Patent Owner.

U.S. Patent No. 8,633,194 to Fanara *et al.*

Issue Date: January 21, 2014

Title: Pharmaceutical composition of piperazine derivatives

Inter Partes Review No.: IPR2019-00400

PETITIONER'S NOTICE OF DEPOSITION OF
DR. SARFARAZ NIAZI

Pursuant to 37 C.F.R. § 42.53, Petitioner Apotex Inc. (“Petitioner”) hereby provides notice that it will conduct cross-examination by deposition of Dr. Sarfaraz Niazi, a witness of Patent Owner UCB Biopharma Sprl (“Patent Owner”). The deposition will begin on December 6, 2019 at 9:00 a.m. (unless otherwise agreed) at the offices of Fenwick & West LLP located at 902 Broadway Suite 14, New York, NY 10010-6035, and will continue until completed. In accordance with 37 C.F.R. § 42.53(d)(1), the parties have conferred and have agreed upon this date and location for the cross-examination of Dr. Niazi.

The cross-examination will be taken before a Notary Public or other officer authorized by law to administer oaths. The cross-examination will be recorded by stenographic and/or audio means. It may also be transcribed by real-time reporting software and recorded by a videographer.

Dated: November 18, 2019

Respectfully submitted,

Katten Muchin Rosenman LLP

By: /Alissa M. Pacchioli/
Alissa M. Pacchioli
Reg. No. 74,252

CERTIFICATION OF SERVICE ON PATENT OWNER

Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4), and 42.105, the undersigned certifies that on November 18, 2019, a complete copy of the foregoing Notice was served via email to Patent Owner's counsel at:

James Trainor: jtrainor@fenwick.com

Robert Counihan: rcounihan@fenwick.com

Erica Sutter: esutter@fenwick.com

Respectfully submitted,

Katten Muchin Rosenman LLP

By: /Alissa M. Pacchioli/

Alissa M. Pacchioli

Reg. No. 74,252